Comparison of Efficacy and Safety Between Domestic and Imported Voriconazole in the Treatment of Pulmonary Fungal Infection After Renal Transplantation

SU Ying; JIN Pengfei; XI Na

doi:10.14009/j.issn.1672-2124.2020.10.002

您当前的位置：

首页 >

文章列表页 >

Comparison of Efficacy and Safety Between Domestic and Imported Voriconazole in the Treatment of Pulmonary Fungal Infection After Renal Transplantation

更新时间：2022-10-08

- Comparison of Efficacy and Safety Between Domestic and Imported Voriconazole in the Treatment of Pulmonary Fungal Infection After Renal Transplantation
- Vol. 20, Issue 10, Pages: 1161-1163(2020)
- 作者机构：
  
  1. 中国人民解放军总医院第八医学中心药剂科
  2. 国家老年医学中心/北京医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.10.002
  CLC： R699.2
- Published：2020，
扫描看全文
[1]苏莹,金鹏飞,西娜.国产与进口伏立康唑用于肾移植术后肺部真菌感染患者的疗效及安全性比较[J].中国医院用药评价与分析,2020,20(10):1161-1163+1167.

SU Ying, JIN Pengfei, XI Na. Comparison of Efficacy and Safety Between Domestic and Imported Voriconazole in the Treatment of Pulmonary Fungal Infection After Renal Transplantation. [J]. 20(10):1161-1163(2020)
[1]苏莹,金鹏飞,西娜.国产与进口伏立康唑用于肾移植术后肺部真菌感染患者的疗效及安全性比较[J].中国医院用药评价与分析,2020,20(10):1161-1163+1167. DOI： 10.14009/j.issn.1672-2124.2020.10.002.

SU Ying, JIN Pengfei, XI Na. Comparison of Efficacy and Safety Between Domestic and Imported Voriconazole in the Treatment of Pulmonary Fungal Infection After Renal Transplantation. [J]. 20(10):1161-1163(2020) DOI： 10.14009/j.issn.1672-2124.2020.10.002.

摘要

目的:探讨国产伏立康唑与进口伏立康唑用于肾移植术后肺部真菌感染患者的疗效及安全性。方法:回顾性选取2018年9月至2020年5月中国人民解放军总医院第八医学中心肾移植术后可疑或确诊为肺部真菌感染的患者60例

按照治疗药物的不同分为国产伏立康唑组和进口伏立康唑组

每组30例。比较两组患者的临床疗效、不良反应发生情况、平均治疗时间和治疗费用的差异。结果:进口伏立康唑组患者的治疗有效率为83. 3%（25/30）

明显高于国产伏立康唑组的63. 2%（19/30）

差异有统计学意义（χ2=5. 08

P=0. 024）。进口伏立康唑组、国产伏立康唑组患者的不良反应发生率分别为13. 3%（4/30）、20. 0%（6/30）

差异无统计学意义（χ2=0. 48

P=0. 49）。进口伏立康唑组患者的平均治疗时间为（19. 35±5. 47） d

平均治疗费用为（35 710. 21±4 762. 18）元;国产伏立康唑组患者的平均治疗时间为（21. 47±6. 25） d

平均治疗费用为（12 248. 05±690. 01）元;进口伏立康唑组患者的治疗费用明显高于国产伏立康唑组

差异有统计学意义（t=29. 03

P <0. 001）。结论:对肾移植术后肺部真菌感染的患者

进口伏立康唑在疗效上优于国产药品

安全性与国产药品未见显著性差异

但治疗费用明显高于国产药品。

Abstract

OBJECTIVE: To probe into the efficacy of safety of domestic and imported voriconazole in the treatment of pulmonary fungal infection after renal transplantation. METHODS: Totally 60 patients with suspected or confirmed pulmonary fungal infection after renal transplantation admitted into the Eighth Medical Center of Chinese PLA General Hospital from Sept. 2018 to May 2020 were retrospectively selected and divided into domestic voriconazole group and imported voriconazole group according to different drug therapy

with 30 cases in each group. Differences in clinical efficacy

incidences of adverse drug reactions

average treatment time and treatment cost were compared between two groups. RESULTS: The total effect of imported voriconazole group was 83. 3%（ 25/30）

which was significantly higher than that of domestic voriconazole group（ 63. 2%

19/30）

with statistically significant difference（ χ2= 5. 08

P = 0. 024）. The incidences of adverse drug reactions of domestic voriconazole group and imported voriconazole group were respectively 13. 3%（ 4/30） and 20. 0%（ 6/30）

the difference had no statistical significance（ χ2= 0. 48

P =0. 49）. The average treatment time of imported voriconazole group was 19. 35 ± 5. 47 days

with the average treatment cost was 35 710. 21 ± 4 762. 18 yuan; the average treatment time of domestic voriconazole group was 21. 47 ± 6. 25 days

with the average treatment cost was 12 248. 05 ± 690. 01 yuan; the treatment cost of imported voriconazole group was significantly higher than that of domestic voriconazole group

with statistically significant difference（ t = 29. 03

P <0. 001）. CONCLUSIONS: For patients with pulmonary fungal infection after renal transplantation

imported voriconazole has better efficacy than domestic voriconazole

while there is no significant difference in safety between two drugs

but the treatment cost of imported voriconazole is significantly higher than that of domestic voriconazole.

关键词

进口国产伏立康唑真菌感染肾移植

Keywords

ImportedDomesticVoriconazoleFungal infectionRenal transplantation

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Study of Amphotericin B and Voriconazole Induction Therapy Combined with Itraconazole Consolidation Therapy in the Treatment of Acquired Immune Deficiency Syndrome Patients with Talaromycosis Marneffei

Therapeutic Drug Monitoring and Influencing Factors of Voriconazole in Patients with Acquired Immunodeficiency Syndrome Complicated with Fungal Infection

Symptom Characteristics and Related Factors of Mental Disorders Induced by Voriconazole

Application of Voriconazole in Patients with Malignant Hematological Disease and Invasive Fungal Infection

Related Author

LI Jinzhuo

LI Xiaoyun

YAN Ruqing

LI Fan

LIU Yanfei

ZHANG Xiaoying

YE Zhenjie

YU Xiaoling

Related Institution

Dept.of Pharmacy, People’s Hospital of Hezhou

Dept.of Infectious Disease, People’s Hospital of Hezhou

Clinical Research Center for Phase Ⅰ, Mengchao Hepatobiliary Hospital of Fujian Medical University

Dept.of Respiratory Medicine,Nanping First Hospital Affiliated to Fujian Medical University

Dept.of Health Outpatient Service,Centers for Disease Control of Fujian Nanping

⁰